---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-089914"
form_type: "8-K"
ticker: "TRAW"
cik: "0001130598"
company_name: "Traws Pharma, Inc."
filed_at: "2024-08-15T23:59:59+00:00"
generated_at: "2026-05-31T08:57:20.727734+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Traws Pharma reports Q2 net loss of $123.1M; $16.9M cash; pipeline milestones ahead

## Summary
- Net loss of $123.1M ($4.87 per share) includes $117.5M non-cash charge from acquired in-process R&D.
- Cash, cash equivalents and short-term investments of $16.9M as of June 30, 2024; adequate through year-end.
- Merger with Trawsfynydd completed April 2024; concurrent $14M private placement from Orbimed and Torrey Pines.
- Tivoxavir marboxil (influenza) Phase 1 dose extension underway; topline results expected Q4 2024.
- Ratutrelvir (COVID-19) completed Phase 1 SAD/MAD; Phase 2 initiation planned Q4 2024/Q1 2025.

## SEC filing metadata
- accession: 0001104659-24-089914
- form_type: 8-K
- ticker: TRAW
- cik: 0001130598
- company_name: Traws Pharma, Inc.
- filed_at: 2024-08-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130598/000110465924089914/0001104659-24-089914-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130598/000110465924089914/tm2421727d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-089914
- JSON: https://secwatch.observer/filing/0001104659-24-089914.json
- Plain text: https://secwatch.observer/filing/0001104659-24-089914.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.